Company profile: BC Platforms
1.1 - Company Overview
Company description
- Provider of data and technology platforms for life sciences and healthcare, enabling access, management, and analysis of clinical, genomic, and omics data. Offers a federated Global Data Network, secure data environments, analytics and AI/federated analytics, and scientific services supporting pharmaceutical research, clinical trials, and real-world data studies.
Products and services
- Data Platform & Analytics: Secure platform enabling pharmaceutical research to access, manage, and analyze clinical, genomics, and omics datasets for precision medicine, delivering analytics within secure environments
- Global Data Network: Federated network connecting stakeholders to real-world, clinical, genomics, and omics data, enabling collaborative research and insights across life sciences and healthcare partners
- AI & Federated Analytics: Secure framework enabling advanced analytics and artificial intelligence for model training and validation, supporting collaborative research in life sciences and healthcare
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BC Platforms
BISC Global
HQ: Belgium
Website
- Description: Provider of bioinformatics, statistics, and machine learning consulting, helping customers overcome challenges in data analysis, pipeline automation, visualization, and compute environments. Consultants work on-site or off-site, project-based or time-based, with a strong focus on communication and deliverables.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BISC Global company profile →
TissueGene
HQ: United States
Website
- Description: Provider of regenerative biopharmaceutical therapies for orthopedic disorders, offering TG-C, an allogeneic cell and gene therapy designed to treat knee osteoarthritis by reducing pain, improving function, and slowing disease progression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TissueGene company profile →
Diagnomics
HQ: United States
Website
- Description: Provider of NGS-based genomics solutions for personalized medicine and next-generation healthcare, offering high-quality R&D and CLIA services including whole genome, exome and RNA sequencing, microarray services, bioinformatics analysis, and clinical/translational research support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnomics company profile →
EpiBiome
HQ: United States
Website
- Description: Provider of precision microbiome engineering focused on developing alternatives to small-molecule antibiotics for use in healthcare, veterinary, and agriculture industries to address antibiotic resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EpiBiome company profile →
Organ-i
HQ: United States
Website
- Description: Provider of novel biotech diagnostic tests for renal diseases, improving clinicians’ ability to monitor the health of transplanted kidneys and providing valuable treatment information for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Organ-i company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BC Platforms
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BC Platforms
2.2 - Growth funds investing in similar companies to BC Platforms
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BC Platforms
4.2 - Public trading comparable groups for BC Platforms
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →